Driven by strong demand from the company's pharma customers, it posted sales of $498 million, beating the average Wall Street estimate of $488.6 million.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Researchers at Pacific Northwest National Laboratory are among those pushing ion mobility spectrometry as a tool to boost complex biological sample analysis.
The company's Q4 revenues were $628.8 million, driven largely by strong pharma and industrial sales; full year 2016 revenues were up 6 percent to $2.17 billion.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The investment bank said the recent pullback in the company's stock has made its valuation more attractive.
Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.
Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.